AR026946A1 - Osteoprotegerina/receptores de factores de necrosis de tumores - Google Patents
Osteoprotegerina/receptores de factores de necrosis de tumoresInfo
- Publication number
- AR026946A1 AR026946A1 ARP000106622A ARP000106622A AR026946A1 AR 026946 A1 AR026946 A1 AR 026946A1 AR P000106622 A ARP000106622 A AR P000106622A AR P000106622 A ARP000106622 A AR P000106622A AR 026946 A1 AR026946 A1 AR 026946A1
- Authority
- AR
- Argentina
- Prior art keywords
- tumor necrosis
- osteoprotegerine
- polypeptides
- receptors
- necrosis factors
- Prior art date
Links
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title 1
- 102000003390 tumor necrosis factor Human genes 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract 2
- 206010054094 Tumour necrosis Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
Abstract
La presente provee nuevos polipétidos similares a osteoprotegerina/receptores de factores de necrosis de tumores y moléculas de ácido nucleico que loscodifican. La presente también provee vectores, células huésped, anticuerpos y métodos para producir polipéptidos similares a osteoprotegerina/receptores defactores de necrosis de tumores. También están provistos métodos para el diagnostico y tratamiento de enfermedades con polipéptidos similares aosteoprotegerina/receptores de factores de necrosis de tumores.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17230699P | 1999-12-16 | 1999-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR026946A1 true AR026946A1 (es) | 2003-03-05 |
Family
ID=22627144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000106622A AR026946A1 (es) | 1999-12-16 | 2000-12-14 | Osteoprotegerina/receptores de factores de necrosis de tumores |
Country Status (8)
Country | Link |
---|---|
US (2) | US20030077246A1 (es) |
EP (1) | EP1238077A1 (es) |
JP (1) | JP2004500063A (es) |
AR (1) | AR026946A1 (es) |
AU (1) | AU2262501A (es) |
CA (1) | CA2394536A1 (es) |
MX (1) | MXPA02006027A (es) |
WO (1) | WO2001044472A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL142557A0 (en) | 1998-10-28 | 2002-03-10 | Snow Brand Milk Products Co Ltd | Remedies for bone metabolic errors |
US7691604B1 (en) | 2000-05-04 | 2010-04-06 | California Institute Of Technology | MRG polypeptides and nucleic acids encoding the same |
US7510845B2 (en) | 2000-05-04 | 2009-03-31 | California Institute Of Technology | Assay employing G protein-coupled receptor expressed in dorsal root ganglia |
US20030092035A1 (en) | 2000-05-04 | 2003-05-15 | Anderson David J. | Pain signaling molecules |
WO2002062852A1 (fr) * | 2001-02-05 | 2002-08-15 | Chugai Seiyaku Kabushiki Kaisha | Proteine receptrice exprimee sur des cellules |
US7198798B2 (en) * | 2001-05-10 | 2007-04-03 | University Of Washington | Methods and devices for promoting endothelial morphogenesis |
NZ530765A (en) | 2001-06-26 | 2006-11-30 | Amgen Fremont Inc | Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases |
AU2003219958B2 (en) * | 2002-02-27 | 2006-01-05 | Immunex Corporation | Polypeptide formulation |
WO2003074084A1 (en) * | 2002-03-01 | 2003-09-12 | Sankyo Company, Limited | A pharmaceutical composition |
AU2003269884A1 (en) * | 2002-05-22 | 2003-12-22 | Incyte Corporation | Receptors and membrane-associated proteins |
US7612169B2 (en) * | 2004-12-13 | 2009-11-03 | Evogenix, Ltd. | Osteoprotegerin variant proteins |
EP3673919A1 (en) | 2005-06-14 | 2020-07-01 | Amgen Inc. | Self-buffering protein formulations |
WO2007010623A1 (ja) * | 2005-07-22 | 2007-01-25 | Phg Corporation | 新規なポリペプチド及びその製造方法 |
US7943328B1 (en) | 2006-03-03 | 2011-05-17 | Prometheus Laboratories Inc. | Method and system for assisting in diagnosing irritable bowel syndrome |
US8286218B2 (en) * | 2006-06-08 | 2012-10-09 | Ajp Enterprises, Llc | Systems and methods of customized television programming over the internet |
US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
NZ621655A (en) | 2009-10-26 | 2015-08-28 | Nestec Sa | Assays for the detection of anti-tnf drugs and autoantibodies |
EP2630495B1 (en) | 2010-10-18 | 2017-02-08 | Nestec S.A. | Methods for determining anti-drug antibody isotypes |
CN103782172A (zh) | 2011-07-06 | 2014-05-07 | 雀巢产品技术援助有限公司 | 检测针对使用TNFα的生物疗法的中和性自体抗体的测定法 |
PT2953634T (pt) | 2013-02-07 | 2021-09-02 | Massachusetts Gen Hospital | Métodos de expansão ou depleção das células t reguladoras |
MX2017007232A (es) | 2014-12-05 | 2017-10-16 | Nestec Sa | Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes. |
AU2016263198C1 (en) * | 2015-05-15 | 2023-10-05 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
CN109476745B (zh) | 2016-05-13 | 2023-11-24 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
JP6884858B2 (ja) | 2016-10-21 | 2021-06-09 | アムジエン・インコーポレーテツド | 医薬製剤及びその製造方法 |
CN112646042A (zh) * | 2019-10-10 | 2021-04-13 | 陕西麦科奥特科技有限公司 | 活性多肽化合物 |
WO2021142573A1 (zh) * | 2020-01-13 | 2021-07-22 | 丁邦 | 一种融合蛋白及其制法和用途 |
CN117136196A (zh) * | 2022-03-03 | 2023-11-28 | 上海赛金生物医药有限公司 | 一种重组融合蛋白的制剂 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US6613544B1 (en) * | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
US6369027B1 (en) * | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
WO2001002568A2 (en) * | 1999-07-02 | 2001-01-11 | Chiron Corporation | Human genes and gene expression products |
-
2000
- 2000-12-14 WO PCT/US2000/033858 patent/WO2001044472A1/en not_active Application Discontinuation
- 2000-12-14 JP JP2001545549A patent/JP2004500063A/ja not_active Withdrawn
- 2000-12-14 CA CA002394536A patent/CA2394536A1/en not_active Abandoned
- 2000-12-14 EP EP00986374A patent/EP1238077A1/en not_active Withdrawn
- 2000-12-14 AR ARP000106622A patent/AR026946A1/es unknown
- 2000-12-14 AU AU22625/01A patent/AU2262501A/en not_active Abandoned
- 2000-12-14 MX MXPA02006027A patent/MXPA02006027A/es unknown
-
2002
- 2002-05-15 US US10/146,574 patent/US20030077246A1/en not_active Abandoned
-
2005
- 2005-01-25 US US11/042,814 patent/US20060024267A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2262501A (en) | 2001-06-25 |
US20060024267A1 (en) | 2006-02-02 |
US20030077246A1 (en) | 2003-04-24 |
JP2004500063A (ja) | 2004-01-08 |
MXPA02006027A (es) | 2002-12-05 |
EP1238077A1 (en) | 2002-09-11 |
CA2394536A1 (en) | 2001-06-21 |
WO2001044472A1 (en) | 2001-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR026946A1 (es) | Osteoprotegerina/receptores de factores de necrosis de tumores | |
BRPI0315666B8 (pt) | dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos | |
MXPA02002384A (es) | Polipeptidos similares al factor de crecimiento de fibroblastos. | |
CY1123400T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
CY1114944T1 (el) | Σταθεροποιημενα αλφα ελικοειδη πεπτιδια και χρησεις αυτων | |
CY1113247T1 (el) | Νουκλεϊνικα οξεα με τιτλο 273ρ4β7 και η χρηση τους στην ανιχνευση καρκινου | |
ATE229073T1 (de) | Protein e25a, methoden zu dessen herstellung und anwendung | |
WO2005005599A3 (en) | Modulation of c-reactive protein expression | |
AR038568A1 (es) | Anticuerpos anti-a beta y su uso | |
DE69617440D1 (de) | Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen | |
DE69833784D1 (de) | Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren | |
BRPI0509177A (pt) | uso de anticorpos anti-alfa5beta1 para inibir a proliferação de células cancerìgenas | |
ATE323770T1 (de) | Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren | |
DK1007537T3 (da) | Receptor-protein med betegnelsen 2F1 | |
ATE353920T1 (de) | Menschlischer monoklonaler antikörper gegen ep- cam und dessen verwendung in krebstherapie | |
AR016436A1 (es) | Proteina que inhibe a la p27, adn que la codifica, anticuerpos y productos de disociacion de los mismos, acido nucleico antisentido, estructura artificialde acido nucleico y la utilizacion de todo esto en terapia y profilaxis de enfermedades | |
DE602005025231D1 (de) | Gene und polypeptide in verbindung mit brustkrebserkrankungen | |
DK1082423T3 (da) | Cyclin E2-gener og -proteiner | |
ES2165506T3 (es) | Antagonistas del il-8 para el tratamiento del asma. | |
DE60026733D1 (de) | Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung | |
WO1999033870A3 (en) | Human regulatory proteins | |
WO1999031128A3 (en) | Human tumor necrosis factor-r2-like proteins | |
UY26170A1 (es) | Antigeno (c42) asociados a tumores | |
WO2000040722A3 (en) | Insulin-synthesis genes | |
DE69828902D1 (de) | Polypeptide mit 5-aminolevulinsäure synthaseaktivität und deren nukleinsäuren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |